Findings

What do systematic reviews say?

18 questions · 18 findings · 2 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 5.6%GRADE not reported 0 · 0%Very low 3 · 16.7%Low 10 · 55.6%Moderate 4 · 22.2%High 0 · 0%

Mycophenolate mofetil vs cyclophosphamide

Death at 6 months · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in death at 6 months compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25 [0.35, 4.46]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Kidney function · adults with renal vasculitis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mycophenolate mofetil vs cyclophosphamide

Dialysis · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1 [0.14, 6.9]
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Relapse · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.8 [1, 3.22]
1 study · 127 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Remission · adults with renal vasculitis

Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.17 [1.01, 1.35]
3 studies · 216 participants
Moderate

Mycophenolate mofetil vs cyclophosphamide

Serious adverse events · adults with renal vasculitis

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.25
1 study · 140 participants
Low

Mycophenolate mofetil vs cyclophosphamide

Infection · adults with renal vasculitis

Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
RR 1.27 [0.75, 2.16]
3 studies · 216 participants
Moderate

Mycophenolate mofetil vs IV cyclophosphamide

Death · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.12 [0.61, 2.06]
8 studies · 826 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

ESKD · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.71 [0.27, 1.84]
3 studies · 231 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

Complete renal remission · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.17 [0.97, 1.42]
8 studies · 828 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Partial renal remission · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
9 studies · 868 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Ovarian failure · patients with induction therapy in lupus nephritis

It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.36 [0.06, 2.18]
3 studies · 539 participants
Very low

Mycophenolate mofetil vs IV cyclophosphamide

Major infection · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.54]
6 studies · 699 participants
Low

Mycophenolate mofetil vs IV cyclophosphamide

Alopecia · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 0.29 [0.19, 0.46]
3 studies · 622 participants
Moderate

Mycophenolate mofetil vs IV cyclophosphamide

Diarrhoea · patients with induction therapy in lupus nephritis

Mycophenolate mofetil (MMF) probably leads to higher diarrhoea compared with IV cyclophosphamide (CPA) (moderate certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.42 [1.64, 3.58]
4 studies · 609 participants
Moderate

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Partial renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1 [0.78, 1.28]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Stable kidney function · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.78 [1.4, 2.26]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Complete renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.38 [1.07, 5.3]
2 studies · 402 participants
Low